2024 ICD-10-CM Diagnosis Code T37.2X6D

Underdosing of antimalarials and drugs acting on other blood protozoa, subsequent encounter

ICD-10-CM Code:
T37.2X6D
ICD-10 Code for:
Underdosing of antimalari/drugs acting on bld protzoa, subs
Is Billable?
Yes - Valid for Submission
Chronic Condition Indicator: [1]
Not chronic
Code Navigator:

Code Classification

  • Injury, poisoning and certain other consequences of external causes
    (S00–T88)
    • Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
      (T36-T50)
      • Poisoning by, adverse effect of and underdosing of other systemic anti-infectives and antiparasitics
        (T37)

T37.2X6D is a billable diagnosis code used to specify a medical diagnosis of underdosing of antimalarials and drugs acting on other blood protozoa, subsequent encounter. The code is valid during the current fiscal year for the submission of HIPAA-covered transactions from October 01, 2023 through September 30, 2024. The code is exempt from present on admission (POA) reporting for inpatient admissions to general acute care hospitals.

This code describes a circumstance which influences the patient's health status but not a current illness or injury. The code is unacceptable as a principal diagnosis.

T37.2X6D is a subsequent encounter code, includes a 7th character and should be used after the patient has completed active treatment for a condition like underdosing of antimalarials and drugs acting on other blood protozoa. According to ICD-10-CM Guidelines a "subsequent encounter" occurs when the patient is receiving routine care for the condition during the healing or recovery phase of treatment. Subsequent diagnosis codes are appropriate during the recovery phase, no matter how many times the patient has seen the provider for this condition. If the provider needs to adjust the patient's care plan due to a setback or other complication, the encounter becomes active again.

Clinical Classification

Clinical Information

  • Amodiaquine

    a 4-aminoquinoline compound with anti-inflammatory properties.
  • Chloroquine

    the prototypical antimalarial agent with a mechanism that is not well understood. it has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
  • Cinchona

    a genus of rubiaceous south american trees that yields the toxic cinchona alkaloids from their bark; quinine; quinidine; chinconine, cinchonidine and others are used to treat malaria and cardiac arrhythmias.
  • Cinchona Alkaloids

    alkaloids extracted from various species of cinchona.
  • Eflornithine

    an inhibitor of ornithine decarboxylase, the rate limiting enzyme of the polyamine biosynthetic pathway.
  • Mefloquine

    a phospholipid-interacting antimalarial drug (antimalarials). it is very effective against plasmodium falciparum with very few side effects.
  • Primaquine

    an aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. it has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. adverse effects include anemias and gi disturbances. (from martindale, the extra pharmacopeia, 30th ed, p404)
  • Proguanil

    a biguanide compound which metabolizes in the body to form cycloguanil, an anti-malaria agent.
  • Pyrimethamine

    one of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis.
  • Quinacrine

    an acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. it has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. it is used in cell biological experiments as an inhibitor of phospholipase a2.
  • Quinacrine Mustard

    nitrogen mustard analog of quinacrine used primarily as a stain in the studies of chromosomes and chromatin. fluoresces by reaction with nucleic acids in chromosomes.
  • Quinine

    an alkaloid derived from the bark of the cinchona tree. it is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. it was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. the mechanisms of its antimalarial effects are not well understood.

Coding Guidelines

Underdosing refers to taking less of a medication than is prescribed by a provider or a manufacturer's instruction. Codes for underdosing should never be assigned as principal or first-listed codes. If a patient has a relapse or exacerbation of the medical condition for which the drug is prescribed because of the reduction in dose, then the medical condition itself should be coded.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of other systemic anti-infectives and antiparasitics (T37). Use the following options for the aplicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Code Edits

The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10-CM Code Edits are applicable to this code:

  • Unacceptable principal diagnosis - There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.

Present on Admission (POA)

T37.2X6D is exempt from POA reporting - The Present on Admission (POA) indicator is used for diagnosis codes included in claims involving inpatient admissions to general acute care hospitals. POA indicators must be reported to CMS on each claim to facilitate the grouping of diagnoses codes into the proper Diagnostic Related Groups (DRG). CMS publishes a listing of specific diagnosis codes that are exempt from the POA reporting requirement. Review other POA exempt codes here.

CMS POA Indicator Options and Definitions

POA IndicatorReason for CodeCMS will pay the CC/MCC DRG?
YDiagnosis was present at time of inpatient admission.YES
NDiagnosis was not present at time of inpatient admission.NO
UDocumentation insufficient to determine if the condition was present at the time of inpatient admission.NO
WClinically undetermined - unable to clinically determine whether the condition was present at the time of inpatient admission.YES
1Unreported/Not used - Exempt from POA reporting. NO

Convert T37.2X6D to ICD-9-CM

  • ICD-9-CM Code: -
    No Map Flag -

Table of Drugs and Chemicals

The parent code T37.2X6 of the current diagnosis code is referenced in the Table of Drugs and Chemicals, this table contains a classification of drugs, industrial solvents, corrosive gases, noxious plants, pesticides, and other toxic agents.

According to ICD-10-CM coding guidelines it is advised to do not code directly from the Table of Drugs and Chemicals, instead always refer back to the Tabular List when doing the initial coding. Each substance in the table is assigned a code according to the poisoning classification and external causes of adverse effects. It is important to use as many codes as necessary to specify all reported drugs, medicinal or chemical substances. If the same diagnosis code describes the causative agent for more than one adverse reaction, poisoning, toxic effect or underdosing, utilize the code only once.

Substance Poisoning
Accidental
(unintentional)
Poisoning
Accidental
(self-harm)
Poisoning
Assault
Poisoning
Undetermined
Adverse
effect
Underdosing
8-Aminoquinoline drugsT37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
AmodiaquineT37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
Amopyroquin (e)T37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
AntimalarialT37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
Antimalarial
  »prophylactic NEC
T37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
Antimalarial
  »pyrimidine derivative
T37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
AralenT37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
CamoquinT37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
ChloroguanideT37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
ChloroquineT37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
ChlorproguanilT37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
CinchonaT37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
Cinchonine alkaloidsT37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
Cycloguanil embonateT37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
DaraprimT37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
EflornithineT37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
GuanatolT37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
HalofantrineT37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
IsopentaquineT37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
MefloquineT37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
MepacrineT37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
PaludrineT37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
Pamaquine (naphthoute)T37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
PentaquineT37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
PrimaquineT37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
ProguanilT37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
PyrimethamineT37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
Pyrimethamine
  »with sulfadoxine
T37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
QuinacrineT37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
QuinineT37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
QuinocideT37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6
Schizontozide (blood) (tissue)T37.2X1T37.2X2T37.2X3T37.2X4T37.2X5T37.2X6

Patient Education


Medication Errors

Medicines treat infectious diseases, prevent problems from chronic diseases, and ease pain. But medicines can also cause harmful reactions if not used correctly. Errors can happen in the hospital, at the health care provider's office, at the pharmacy, or at home. You can help prevent errors by:

  • Knowing your medicines. When you get a prescription, ask the name of the medicine and check to make sure that the pharmacy gave you the right medicine. Make sure that you understand how often you should take the medicine and how long you should take it.
  • Keeping a list of medicines.
    • Write down all of the medicines that you are taking, including the names of your medicines, how much you take, and when you take them. Make sure to include any over-the-counter medicines, vitamins, supplements, and herbs that you take.
    • List the medicines that you are allergic to or that have caused you problems in the past.
    • Take this list with you every time you see a health care provider.
  • Reading medicine labels and following the directions. Don't just rely on your memory - read the medication label every time. Be especially careful when giving medicines to children.
  • Asking questions. If you don't know the answers to these questions, ask your health care provider or pharmacist:
    • Why am I taking this medicine?
    • What are the common side effects?
    • What should I do if I have side effects?
    • When should I stop this medicine?
    • Can I take this medicine with the other medicines and supplements on my list?
    • Do I need to avoid certain foods or alcohol while taking this medicine?

Food and Drug Administration


[Learn More in MedlinePlus]

Code History

  • FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
  • FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
  • FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.